Pernix Therapeutics announces result of bid process for acquisition of Contrave®
Pernix Therapeutics announced that Nalpropion Pharmaceuticals, the special purpose vehicle (“SPV”) created by Pernix and an investor group, has been informed by Orexigen that no other bids for Orexigen’s assets were received by the court-approved bid deadline. June 22, 2018